Allianz Asset Management
ADCT icon

Allianz Asset Management’s ADC Therapeutics ADCT Stock Holding History

Allianz Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-61,760
Closed -$491K – 1871
2022
Q2 		$491K Sell
61,760
-6,050
-9% -$57.2K ﹤0.01% 1897
2022
Q1 		$997K Buy
67,810
+9,780
+17% +$155K ﹤0.01% 1860
2021
Q4 		$1.18M Buy
58,030
+9,860
+20% +$238K ﹤0.01% 1832
2021
Q3 		$1.31M Buy
48,170
+27,655
+135% +$708K ﹤0.01% 1811
2021
Q2 		$500K Sell
20,515
-42,075
-67% -$976K ﹤0.01% 2034
2021
Q1 		$1.53M Hold
62,590
– – ﹤0.01% 1499
2020
Q4 		$2M Buy
+62,590
New +$2.05M ﹤0.01% 1314

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $901M AUM 28.6% 1-Year Est. Return

Allianz Asset Management's ADCT Position: Q3 2022 in Review

Allianz Asset Management sold out of ADC Therapeutics (ADCT) in Q3 2022, closing a stake of 61,760 shares — an estimated $491K sold.

Allianz Asset Management first reported a position in ADCT in Q4 2020 and held it in 7 quarters. The position peaked at $2M in Q4 2020. 66 funds tracked by Wall St. Rank hold ADCT as of Q3 2022.

  • Allianz Asset Management reported no remaining ADC Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Allianz Asset Management sold 61,760 ADC Therapeutics shares in Q3 2022, an estimated $491K.
  • Allianz Asset Management first reported a position in ADC Therapeutics in Q4 2020 and held it in 7 quarters.
  • Allianz Asset Management's ADC Therapeutics position peaked at $2M in Q4 2020.
  • 66 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2022.

Based on Allianz Asset Management's 13F filing for Q3 2022, filed 8 Nov 2022.